Literature DB >> 22099359

Physical functioning in boys with hemophilia in the U.S.

Paul E Monahan1, Judith R Baker, Brenda Riske, J Michael Soucie.   

Abstract

BACKGROUND: Hemophilia is the most common inherited severe bleeding disorder. Although the most frequent complication of repeated hemorrhages is a crippling joint disease that begins in childhood, the extent of resultant joint functional impairment varies widely within the hemophilia population.
PURPOSE: The goal of this exploratory analysis was to examine a national database that collects information on boys with hemophilia, an X-linked severe congenital bleeding disorder, to determine characteristics associated with increased risk of developing limitations in physical functioning as an outcome of recurrent hemorrhages.
METHODS: A standard set of data is collected annually at ∼130 U.S. comprehensive hemophilia treatment centers (HTCs) in a voluntary surveillance program called the Universal Data Collection (UDC) program. Fifteen potential predictors for poor outcomes of physical functioning related to bleeding were examined for boys (aged ≤ 18 years) from 1998 to 2008. Bivariate and multivariate analyses of these predictors performed in 2009 examined associations with self-reported limitation of activities, absenteeism from work or school, and reliance on assistive devices for ambulation and mobility.
RESULTS: Multiple characteristics of underlying hemophilia severity and disease chronicity (in particular, increasing age, presence of joint bleeding, and inhibitor antibodies) were independently associated with increased risk of limitations of physical function. Nonwhite race/ethnicity was associated with each of the poorer functional outcomes in bivariate analyses. After controlling for the potential confounding effects of the multiple population characteristics on race, only African-American race was independently associated with activity restrictions, and African-American and Asian/Pacific Island ethnicity with absenteeism. With the exception of indicators of underlying disease severity, only obesity and medical insurance coverage with Medicaid rather than commercial insurance were independently associated with multiple poor outcomes.
CONCLUSIONS: Interventions focused on eliminating inhibitors, improving outcomes for African-American children with hemophilia, and maintaining healthy body weight are warranted. In addition, strategies are needed to assure adequate insurance coverage for all people with hemophilia to eliminate economic barriers to optimal functional outcomes.
Copyright © 2011 American Journal of Preventive Medicine. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22099359     DOI: 10.1016/j.amepre.2011.09.017

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  15 in total

1.  Public health surveillance and data collection: general principles and impact on hemophilia care.

Authors:  J Michael Soucie
Journal:  Hematology       Date:  2012-04       Impact factor: 2.269

2.  Implementing emicizumab in hemophilia inhibitor management: emicizumab should be prescribed after tolerance.

Authors:  Guy Young
Journal:  Blood Adv       Date:  2018-10-23

3.  Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project.

Authors:  Marilyn J Manco-Johnson; J Michael Soucie; Joan Cox Gill
Journal:  Blood       Date:  2017-02-09       Impact factor: 22.113

4.  The role of disease severity in influencing body mass index in people with haemophilia: a single-institutional cross-sectional study.

Authors:  M McNamara; A Antun; C L Kempton
Journal:  Haemophilia       Date:  2013-10-14       Impact factor: 4.287

5.  Differences in bleeding phenotype and provider interventions in postmenarchal adolescents when compared to adult women with bleeding disorders and heavy menstrual bleeding.

Authors:  L V Srivaths; Q C Zhang; V R Byams; J E Dietrich; A H James; P A Kouides; R Kulkarni
Journal:  Haemophilia       Date:  2017-09-05       Impact factor: 4.287

Review 6.  Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review.

Authors:  C H Miller
Journal:  Haemophilia       Date:  2018-02-15       Impact factor: 4.287

7.  Evaluating the psychometric properties of the EQ-5D-5L and SF-6D among patients with haemophilia.

Authors:  Richard Huan Xu; Dong Dong; Nan Luo; Eliza Lai-Yi Wong; Yushan Wu; Siyue Yu; Renchi Yang; Junshuai Liu; Huiqin Yuan; Shuyang Zhang
Journal:  Eur J Health Econ       Date:  2021-03-24

Review 8.  Care models in the management of haemophilia: a systematic review.

Authors:  C H T Yeung; N Santesso; M Pai; C Kessler; N S Key; M Makris; T Navarro-Ruan; J M Soucie; H J Schünemann; A Iorio
Journal:  Haemophilia       Date:  2016-07       Impact factor: 4.287

9.  Risk factors for cardiovascular disease in children and young adults with haemophilia.

Authors:  Jacqueline Limjoco; Courtney D Thornburg
Journal:  Haemophilia       Date:  2018-07-13       Impact factor: 4.287

10.  An inventory of healthy weight practices in federally funded haemophilia treatment centres in the United States.

Authors:  E Adams; J Deutsche; E Okoroh; S Owens-McAlister; S Majumdar; M Ullman; M L Damiano; M Recht
Journal:  Haemophilia       Date:  2014-03-16       Impact factor: 4.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.